<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">34667307</PMID><DateCompleted><Year>2021</Year><Month>12</Month><Day>14</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1474-1741</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>12</Issue><PubDate><Year>2021</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Nature reviews. Immunology</Title><ISOAbbreviation>Nat Rev Immunol</ISOAbbreviation></Journal><ArticleTitle>The immunology of asymptomatic SARS-CoV-2 infection: what are the key questions?</ArticleTitle><Pagination><StartPage>762</StartPage><EndPage>768</EndPage><MedlinePgn>762-768</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41577-021-00631-x</ELocationID><Abstract><AbstractText>An important challenge during the COVID-19 pandemic has been to understand asymptomatic disease and the extent to which this may be a source of transmission. As asymptomatic disease is by definition hard to screen for, there is a lack of clarity about this aspect of the COVID-19 spectrum. Studies have considered whether the prevalence of asymptomatic disease is determined by differences in age, demographics, viral load, duration of shedding, and magnitude or durability of immunity. It is clear that adaptive immunity is strongly activated during asymptomatic infection, but some features of the T cell and antibody response may differ from those in symptomatic disease. Areas that need greater clarity include the extent to which asymptomatic disease leads to persistent symptoms (long COVID), and the quality, quantity and durability of immune priming required to confer subsequent protection.</AbstractText><CopyrightInformation>&#xa9; 2021. Springer Nature Limited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Boyton</LastName><ForeName>Rosemary J</ForeName><Initials>RJ</Initials><Identifier Source="ORCID">0000-0002-5608-0797</Identifier><AffiliationInfo><Affiliation>Department of Infectious Disease, Faculty of Medicine, Imperial College London, London, UK. r.boyton@imperial.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Lung Division, Royal Brompton and Harefield Hospitals, Guy's and St. Thomas' NHS Foundation Trust, London, UK. r.boyton@imperial.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Altmann</LastName><ForeName>Daniel M</ForeName><Initials>DM</Initials><Identifier Source="ORCID">0000-0002-2436-6192</Identifier><AffiliationInfo><Affiliation>Department of Immunology and Inflammation, Faculty of Medicine, Imperial College London, London, UK. d.altmann@imperial.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MC_PC_20031</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_PC_20060</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/S019553/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/R02622X/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/W020610/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/V036939/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>10</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Rev Immunol</MedlineTA><NlmUniqueID>101124169</NlmUniqueID><ISSNLinking>1474-1733</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058345" MajorTopicYN="Y">Asymptomatic Infections</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000635" MajorTopicYN="Y">transmission</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007156" MajorTopicYN="Y">Immunologic Memory</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>R.J.B. and D.M.A. are members of the Global T cell Expert Consortium and have consulted for Oxford Immunotec outside the submitted work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>9</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>10</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>10</Month><Day>20</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>10</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34667307</ArticleId><ArticleId IdType="pmc">PMC8525456</ArticleId><ArticleId IdType="doi">10.1038/s41577-021-00631-x</ArticleId><ArticleId IdType="pii">10.1038/s41577-021-00631-x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gandhi M, Yokoe DS, Havlir DV. Asymptomatic transmission, the Achilles&#x2019; heel of current strategies to control Covid-19. N. Engl. J. Med. 2020;382:22&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7200054</ArticleId><ArticleId IdType="pubmed">32329972</ArticleId></ArticleIdList></Reference><Reference><Citation>Savvides C, Siegel R. Asymptomatic and presymptomatic transmission of SARS-CoV-2: a systematic review. medRxiv. 2020 doi: 10.1101/2020.06.11.20129072.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.06.11.20129072</ArticleId><ArticleId IdType="pmc">PMC7310638</ArticleId><ArticleId IdType="pubmed">32587980</ArticleId></ArticleIdList></Reference><Reference><Citation>Byrne AW, et al. Inferred duration of infectious period of SARS-CoV-2: rapid scoping review and analysis of available evidence for asymptomatic and symptomatic COVID-19 cases. BMJ Open. 2020;10:e039856.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7409948</ArticleId><ArticleId IdType="pubmed">32759252</ArticleId></ArticleIdList></Reference><Reference><Citation>Mok CKP, et al. T-cell responses to MERS coronavirus infection in people with occupational exposure to dromedary camels in Nigeria: an observational cohort study. Lancet Infect. Dis. 2020 doi: 10.1016/S1473-3099(20)30599-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(20)30599-5</ArticleId><ArticleId IdType="pmc">PMC7538089</ArticleId><ArticleId IdType="pubmed">33035474</ArticleId></ArticleIdList></Reference><Reference><Citation>Arons MM, et al. Presymptomatic SARS-CoV-2 infections and transmission in a skilled nursing facility. N. Engl. J. Med. 2020;382:2081&#x2013;2090.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7200056</ArticleId><ArticleId IdType="pubmed">32329971</ArticleId></ArticleIdList></Reference><Reference><Citation>Ward H, et al. SARS-CoV-2 antibody prevalence in England following the first peak of the pandemic. Nat. Commun. 2021;12:905.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7876103</ArticleId><ArticleId IdType="pubmed">33568663</ArticleId></ArticleIdList></Reference><Reference><Citation>Pollan M, et al. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. Lancet. 2020;396:535&#x2013;544.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7336131</ArticleId><ArticleId IdType="pubmed">32645347</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilmes P, et al. SARS-CoV-2 transmission risk from asymptomatic carriers: Results from a mass screening programme in Luxembourg. Lancet Reg. Health Eur. 2021;4:100056.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7912359</ArticleId><ArticleId IdType="pubmed">33997830</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyerowitz EA, et al. Towards an accurate and systematic characterisation of persistently asymptomatic infection with SARS-CoV-2. Lancet Infect. Dis. 2021;21:e163&#x2013;e169.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7834404</ArticleId><ArticleId IdType="pubmed">33301725</ArticleId></ArticleIdList></Reference><Reference><Citation>Long Q-X, et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat. Med. 2020;26:1200&#x2013;1204.</Citation><ArticleIdList><ArticleId IdType="pubmed">32555424</ArticleId></ArticleIdList></Reference><Reference><Citation>Kronbichler A, et al. Asymptomatic patients as a source of COVID-19 infections: a systematic review and meta-analysis. Int. J. Infect. Dis. 2020;98:180&#x2013;186.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7832751</ArticleId><ArticleId IdType="pubmed">32562846</ArticleId></ArticleIdList></Reference><Reference><Citation>Buitrago-Garcia EGD, et al. Occurrence and transmission potential of asymptomatic SARS-CoV-2 infections: a living systematic review and meta-analysis. PLoS Med. 2020;17:e1003346.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7508369</ArticleId><ArticleId IdType="pubmed">32960881</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsitilonis OE, et al. SARS-CoV-2 infection is asymptomatic in nearly half of adults with robust anti-spike protein receptor binding domain antibody response. Vaccines. 2021;9:207.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7998869</ArticleId><ArticleId IdType="pubmed">33801380</ArticleId></ArticleIdList></Reference><Reference><Citation>Lavezzo E, et al. Suppression of a SARS-CoV-2 outbreak in the Italian municipality of Vo&#x2019;. Nature. 2020;584:425.</Citation><ArticleIdList><ArticleId IdType="pubmed">32604404</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao S, et al. Post-lockdown SARS-CoV-2 nucleic acid screening in nearly ten million residents of Wuhan. China. Nat. Commun. 2020;11:5917.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7679396</ArticleId><ArticleId IdType="pubmed">33219229</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffin S. Covid-19: asymptomatic cases may not be infectious, Wuhan study indicates. BMJ. 2020;371:m4695.</Citation><ArticleIdList><ArticleId IdType="pubmed">33262115</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsukagoshy H, et al. Relationship between viral load and the clinical course of Covid-19. Viruses. 2021;13:304.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7919281</ArticleId><ArticleId IdType="pubmed">33672005</ArticleId></ArticleIdList></Reference><Reference><Citation>Nikolai LA, et al. Asymptomatic SARS coronavirus 2 infection: invisible yet invincible. Intl J. Inf. Dis. 2020;100:112&#x2013;116.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7470698</ArticleId><ArticleId IdType="pubmed">32891737</ArticleId></ArticleIdList></Reference><Reference><Citation>Altmann DM. Children and the return to school: how much should we worry about covid-19 and long covid? BMJ. 2021 doi: 10.1136/bmj.n701.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n701</ArticleId><ArticleId IdType="pubmed">33722798</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, et al. The temporal association of introducing and lifting non-pharmaceutical interventions with the time-varying reproduction number (R) of SARS-CoV-2: a modelling study across 131 countries. Lancet Infect. Dis. 2020;21:193&#x2013;212.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7581351</ArticleId><ArticleId IdType="pubmed">33729915</ArticleId></ArticleIdList></Reference><Reference><Citation>Sah P, et al. Asymptomatic SARS-CoV-2 infection: a systematic review and meta-analysis. Proc. Natl Acad. Sci. USA. 2021;18:e2109229118.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8403749</ArticleId><ArticleId IdType="pubmed">34376550</ArticleId></ArticleIdList></Reference><Reference><Citation>ISARIC4C. Age, sex and status at 28 days after admission. Dynamic ISARIC4C / CO-CIN report to SAGE and NERVTAG. isaric4chttps://isaric4c.net/reports/ (2021).</Citation></Reference><Reference><Citation>Johansson MA, et al. SARS-CoV-2 transmission from people without COVID-19 symptoms. JAMA Netw. Open. 2021;4:e2035057.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7791354</ArticleId><ArticleId IdType="pubmed">33410879</ArticleId></ArticleIdList></Reference><Reference><Citation>Rasmussen AL, Popescu SV. SAR-CoV-2 transmission without symptoms. Science. 2021;371:1206&#x2013;1207.</Citation><ArticleIdList><ArticleId IdType="pubmed">33737476</ArticleId></ArticleIdList></Reference><Reference><Citation>Rivett L, et al. Screening of healthcare workers for SARS-CoV-2 highlights the role of asymptomatic carriage in COVID-19 transmission. eLife. 2020;9:e58728.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7314537</ArticleId><ArticleId IdType="pubmed">32392129</ArticleId></ArticleIdList></Reference><Reference><Citation>Raffle AE, Gill M. Mass screening for asymptomatic SARS-CoV-2 infection. A misguided policy unlikely to reduce transmission. BMJ. 2020;373:n1058.</Citation><ArticleIdList><ArticleId IdType="pubmed">33910784</ArticleId></ArticleIdList></Reference><Reference><Citation>Cevik M, et al. Prevalence of asymptomatic SARS-CoV-2 infection. Ann. Intern. Med. 2021;174:283&#x2013;284.</Citation><ArticleIdList><ArticleId IdType="pubmed">33587875</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Vinh Chau N, et al. The natural history and transmission potential of asymptomatic severe acute respiratory syndrome coronavirus 2 infection. Clin. Infect. Dis. 2020;71:2679&#x2013;2687.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7314145</ArticleId><ArticleId IdType="pubmed">32497212</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, et al. Characterisation of an asymptomatic cohort of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infected individuals outside of Wuhan, China. Clin. Infect. Dis. 2020;71:2132&#x2013;2137.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7314201</ArticleId><ArticleId IdType="pubmed">32442265</ArticleId></ArticleIdList></Reference><Reference><Citation>Carter RJ, et al. Widespread severe acute respiratory syndrome coronavirus 2 transmission among attendees at a large motorcycle rally and their contacts, 30 US jurisdictions, August-September, 2020. Clin. Infect. Dis. 2021;73:S106&#x2013;S109.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8135316</ArticleId><ArticleId IdType="pubmed">33912907</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones TC, et al. Estimating infectiousness throughout SARS-CoV-2 infection course. Science. 2021;373:eabi5273.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9267347</ArticleId><ArticleId IdType="pubmed">34035154</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Hare, R. First volunteers on COVID-19 human challenge study leave quarantine. Imperial College Londonhttps://www.imperial.ac.uk/news/218294/first-volunteers-covid-19-humanchallenge-study/ (2021).</Citation></Reference><Reference><Citation>Davis HE, et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMed. 2021 doi: 10.1016/j.eclinm.2021.101019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2021.101019</ArticleId><ArticleId IdType="pmc">PMC8280690</ArticleId><ArticleId IdType="pubmed">34308300</ArticleId></ArticleIdList></Reference><Reference><Citation>King&#x2019;s College London News Centre. Up to one in six people with COVID-19 report long COVID symptoms. King&#x2019;s College Londonhttps://www.kcl.ac.uk/news/up-to-one-in-six-people-covid-19-long-covid-symptoms (2021).</Citation></Reference><Reference><Citation>Nalbandian A, et al. Post-acute COVID-19 syndrome. Nat. Med. 2021;27:601&#x2013;615.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Office for National Statistics. Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK: 1 April 2021. ONShttps://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/prevalenceofongoingsymptomsfollowingcoronaviruscovid19infectionintheuk/1april2021 (2021).</Citation></Reference><Reference><Citation>Huang, Y. et al. COVID symptoms, symptom clusters, and predictors for becoming a long-hauler: looking for clarity in the haze of the pandemic. Preprint at medRxiv10.1101/2021.03.03.21252086medRxiv (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9510954</ArticleId><ArticleId IdType="pubmed">36154716</ArticleId></ArticleIdList></Reference><Reference><Citation>The BMJ Opinion. The pros and cons of &#x201c;Freedom Day&#x201d; &#x2014; a view from immunology. BMJhttps://blogs.bmj.com/bmj/2021/07/14/the-pros-and-cons-of-freedom-day-a-view-from-immunology/ (2021).</Citation></Reference><Reference><Citation>FAIR Health. A detailed study of patients with long-haul COVID. An Analysis of Private Healthcare Claims. https://s3.amazonaws.com/media2.fairhealth.org/whitepaper/asset/A%20Detailed%20Study%20of%20Patients%20with%20Long-Haul%20COVID--An%20Analysis%20of%20Private%20Healthcare%20Claims--A%20FAIR%20Health%20White%20Paper.pdf (2021).</Citation></Reference><Reference><Citation>Ng LFP. Immunopathology of chikungunya virus infection: lessons learned from patients and animal models. Annu. Rev. Virol. 2017;29:413&#x2013;427.</Citation><ArticleIdList><ArticleId IdType="pubmed">28637387</ArticleId></ArticleIdList></Reference><Reference><Citation>Altmann DM, Boyton RJ. SARS-CoV-2 T cell immunity: specificity, function, durability, and role in protection. Sci. Immunol. 2020;5:eabd6160.</Citation><ArticleIdList><ArticleId IdType="pubmed">32680954</ArticleId></ArticleIdList></Reference><Reference><Citation>Rydyznski Moderbacher C, et al. Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity. Cell. 2020;183:996&#x2013;1012.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7494270</ArticleId><ArticleId IdType="pubmed">33010815</ArticleId></ArticleIdList></Reference><Reference><Citation>Han H, et al. Descriptive, retrospective study of the clinical characteristics of asymptomatic COVID-19 patients. mSphere. 2020;5:e00922-20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7568656</ArticleId><ArticleId IdType="pubmed">33028689</ArticleId></ArticleIdList></Reference><Reference><Citation>Letko M, et al. Bat-borne virus diversity, spillover and emergence. Nat. Rev. Microbiol. 2020;18:461&#x2013;471.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7289071</ArticleId><ArticleId IdType="pubmed">32528128</ArticleId></ArticleIdList></Reference><Reference><Citation>Swadling L, et al. Pre-existing polymerase-specific T cells expand in abortive seronegative SARS-CoV-2 infection. medRxiv. 2021 doi: 10.1101/2021.06.26.21259239.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.06.26.21259239</ArticleId><ArticleId IdType="pmc">PMC8732273</ArticleId><ArticleId IdType="pubmed">34758478</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta RK, et al. Blood transcriptional biomarkers of acute viral infection for detection of pre-symptomatic SARS-CoV-2 infection: a nested, case-control diagnostic accuracy study. Lancet Microbe. 2021 doi: 10.1016/S2666-5247(21)00146-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2666-5247(21)00146-4</ArticleId><ArticleId IdType="pmc">PMC8260104</ArticleId><ArticleId IdType="pubmed">34250515</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarjour NN, Masopust D, Jameson SC. T cell memory: understanding COVID-19. Immunity. 2021;54:14&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7749639</ArticleId><ArticleId IdType="pubmed">33406391</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao X-N, et al. Longitudinal single-cell immune profile revealed distinct innate immune response in asymptomatic COVID-19 patients. bioRxiv. 2020 doi: 10.1101/2020.09.02.276865.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.09.02.276865</ArticleId><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Bozzano F, et al. Extensive activation, tissue trafficking, turnover and functional impairment of NK cells in COVID-19 patients at disease onset associates with subsequent disease severity. PLoS Pathog. 2021;17:e1009448.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8081333</ArticleId><ArticleId IdType="pubmed">33861802</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravikanth V, et al. A variant in TMPRSS2 is associated with decreased disease severity in COVID-19. Meta Gene. 2021;29:100930.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8161869</ArticleId><ArticleId IdType="pubmed">34075330</ArticleId></ArticleIdList></Reference><Reference><Citation>den Hartog G, et al. Persistence of antibodies to SARS-CoV-2 in relation to symptoms in a nationwide prospective study. Clin. Infect. Dis. 2021 doi: 10.1093/cid/ciab172.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciab172</ArticleId><ArticleId IdType="pmc">PMC7929058</ArticleId><ArticleId IdType="pubmed">33624751</ArticleId></ArticleIdList></Reference><Reference><Citation>Reynolds CJ, et al. Discordant neutralizing antibody and T cell responses in asymptomatic and mild SARS-CoV-2 infection. Sci. Immunol. 2020;5:eabf3698.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8101131</ArticleId><ArticleId IdType="pubmed">33361161</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorigatti I, et al. SARS-CoV-2 antibody dynamics and transmission from community-wide serological testing in the Italian municipality of Vo&#x2019;. Nat. Commun. 2021;12:4383.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8289856</ArticleId><ArticleId IdType="pubmed">34282139</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanshylla K, et al. Kinetics and correlates of the neutralising antibody response to SARS-CoV-2 infection in humans. Cell Host Microbe. 2021;29:1&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8090990</ArticleId><ArticleId IdType="pubmed">33984285</ArticleId></ArticleIdList></Reference><Reference><Citation>Graham C, et al. Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 spike is impacted by the B.1.1.7 variant. Immunity. 2021;54:1276&#x2013;1289.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8015430</ArticleId><ArticleId IdType="pubmed">33836142</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021;397:220&#x2013;232.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7833295</ArticleId><ArticleId IdType="pubmed">33428867</ArticleId></ArticleIdList></Reference><Reference><Citation>Montague Z, et al. Dynamics of B cell repertoires and emergence of cross-reactive responses in patients with different severities of COVID-19. Cell Rep. 2021;35:109713.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8106887</ArticleId><ArticleId IdType="pubmed">33991510</ArticleId></ArticleIdList></Reference><Reference><Citation>Sekine T, et al. Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19. Cell. 2020;183:158&#x2013;16827.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7427556</ArticleId><ArticleId IdType="pubmed">32979941</ArticleId></ArticleIdList></Reference><Reference><Citation>Noh JY, et al. Longitudinal assessment of anti-SARS-CoV-2 immune responses for six months based on the clinical severity of COVID-19. J. Infect. Dis. 2021 doi: 10.1093/infdis/jiab124.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiab124</ArticleId><ArticleId IdType="pmc">PMC7989218</ArticleId><ArticleId IdType="pubmed">34467985</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Bert N, et al. Highly functional virus-specific cellular immune response in asymptomatic SARS-CoV-2 infection. J. Exp. Med. 2021;218:e20202617.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7927662</ArticleId><ArticleId IdType="pubmed">33646265</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie C, et al. Association of early inflammation with age and asymptomatic disease in COVID-19. J. Inflamm. Res. 2021;14:1207&#x2013;1216.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8020811</ArticleId><ArticleId IdType="pubmed">33833543</ArticleId></ArticleIdList></Reference><Reference><Citation>Manisty C, et al. Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals. Lancet. 2021;397:1057&#x2013;1058.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7972310</ArticleId><ArticleId IdType="pubmed">33640038</ArticleId></ArticleIdList></Reference><Reference><Citation>Krammer F, et al. Antibody responses in seropositive persons after a single dose of SARS-CoV-2 mRNA vaccine. N. Engl. J. Med. 2021;384:1372&#x2013;1374.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8008743</ArticleId><ArticleId IdType="pubmed">33691060</ArticleId></ArticleIdList></Reference><Reference><Citation>Goel RR, et al. Distinct antibody and memory B cell responses in SARS-CoV-2 na&#xef;ve and recovered individuals following mRNA vaccination. Sci. Immunol. 2021;6:eabi6950.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8158969</ArticleId><ArticleId IdType="pubmed">33858945</ArticleId></ArticleIdList></Reference><Reference><Citation>Reynolds CJ, et al. Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose. Science. 2021;30:eabh1282.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8168614</ArticleId><ArticleId IdType="pubmed">33931567</ArticleId></ArticleIdList></Reference><Reference><Citation>Loyal L, et al. Cross-reactive CD4+ T cells enhance SARS-CoV-2 immune responses upon infection and vaccination. Science. 2021 doi: 10.1126/science.abh1823.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abh1823</ArticleId><ArticleId IdType="pmc">PMC10026850</ArticleId><ArticleId IdType="pubmed">34465633</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>